Sundial: Analysts Expect Positive EBITDA For Q3 2021

Sundial Growers (NASDAQ: SNDL) announced that they will be reporting their third quarter financials after the markets close on November 10th.

Analysts have a consensus US$0.71 12-month price target on the company, via a total of 5 analysts, with 4 analysts having hold ratings, and one other analyst has a sell rating on the company. The street high comes from ATB Capital Markets with a US$0.80 price target, and the lowest target comes from Cantor Fitzgerald with a US$0.00 price target.

Only 4 analysts have revenue estimates for the third quarter. The mean between all 4 is C$16.48 million; this number has been remained flat since the start of May. The street high is C$19.1 million while the lowest sits at C$11.40 million.

Only two analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 35.3%, with this number being flat at the start of May. Street high is a 40.6% estimate and the lowest sits at 30%.

Onto EBITDA estimates, there are currently only 3 analysts who have third-quarter EBITDA estimates. The mean is currently C$0.97 million, with this number being slightly higher than at the start of May. Street high sits at C$2 million EBITDA and the lowest being a (C$0.4) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Moon River Moly: The Davidson Moly-Copper-Tungsten PEA

Integra: The DeLamar Heap Leach Feasibility Study

Highlander Silver: The Saviour Of Bear Creek Mining

Recommended

Steadright Subsidiary NSM Capital Sarl Applies For License At Titanbeach One

Goliath Resources Accelerates Option Agreement On Golddigger While Reducing NSR

Related News

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM

Cresco Labs: Canaccord Maintains Price Target Following FY2020 Results

Last week, Cresco Labs (CSE: CL) reported their fourth quarter and full-year 2020 financial results....

Monday, March 29, 2021, 11:44:00 AM

Cresco Labs: Canaccord Bumps Price Target Up To $20.50

Wednesday, Canaccord came out with their updated valuations for the large three multi-state operators. With...

Sunday, January 17, 2021, 01:41:00 PM

Sundial Growers Drops Two Tiers At Nasdaq To Avoid Near Term Reverse Split

Sundial Growers (NASDAQ: SNDL) appears to be doing all that it can to avoid being...

Friday, December 11, 2020, 08:46:46 AM

ReconAfrica: Haywood Lifts Price Target To $16.00 Following Operational Update

On June 24th, ReconAfrica (CVE: RECO) provided an operational and COVID-19 update, wherein the company...

Monday, June 28, 2021, 11:36:00 AM